Episurf Medical’s 50th Episealer® implant in Belgium
Episurf Medical announces that the 50th implantation of the Episealer® knee implant in Belgium will take place in the near future. Episurf Medical started on a small scale in Belgium, working with a limited number of surgeons. The company’s technology has been very well received by key surgeons in the country and Belgium is one of the company's prioritised markets.
“I am excited to experience an increased acceptance and demand for our Episealer® implants. We have reimbursement arranged in Belgium and are now also able to show positive clinical outcome to surgeons. This is very important as surgeons and patients are looking for proven medical solutions”, says Tania Bol, Regional Manager for Episurf Medical in Belgium and the Netherlands.
“Following a start on a small scale in Belgium, we now see an increasing usage and demand. In combination with positive patient outcomes, this is a very satisfying development in Belgium”, comments Professor Leif Ryd, Senior Medical Advisor, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.05 CEST on 31 August 2017.
Tags: